Rapid heart rate Nausea and vomiting Diagnosis Inguinal hernia is most often diagnosed through a medical history and physical examination. Your doctor will ask you questions about hernia symptoms.

TELA Bio Announces European Commercial Launch of OviTex® Inguinal for Robotic and Laparoscopic Inguinal Hernia Repair TELA Bio, Inc. - GlobeNewswire - Tue Jun 3, 3:05PM CDT ...

Based on market research, inguinal hernia repair is the most common type of hernia repair MALVERN, Pa., June 03, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical ...

MALVERN, Pa. - TELA Bio, Inc. (NASDAQ: TELA), a medical technology company with annual revenues of $71.2 million and impressive revenue growth of 12.8% in the last twelve months, has announced the ...

OviTex Inguinal will be showcased this week at the European Hernia Society (EHS) Annual Congress in Paris, France, where the TELA Bio team will highlight the product’s design features and ...

MALVERN, Pa., June 03, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions ...

A retrospective study led by Dr. Paul Szotek highlighted a low recurrence rate of 1.2% in patients who underwent robotic inguinal hernia repair using OviTex, with an average follow-up of 1.5 years.

Based on market research, inguinal hernia repair is the most common type of hernia repairMALVERN, Pa., June 03, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical ...

Based on market research, inguinal hernia repair is the most common type of hernia repairMALVERN, Pa., June 03, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical ...

TELA Bio Announces European Commercial Launch of OviTex® Inguinal for Robotic and Laparoscopic Inguinal Hernia Repair Provided by GlobeNewswire Jun 3, 2025, 1:05:00 PM ...

This milestone follows the successful U.S. launch of OviTex Inguinal in 2024, where it has achieved over $1 million in sales in its first year and has seen growing adoption by surgeons seeking a ...